Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

Allan Lipton; Harold A. Harvey; Bellarmine Lawrence; Robert Gottlieb; Miodrag Kukrika; Richard Dixon; William Graham; Stephen Miller; Robert Heckard; Dale Schelzel; Deborah S. White

doi:10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

Allan Lipton, Harold A. Harvey, Bellarmine Lawrence, Robert Gottlieb, Miodrag Kukrika, Richard Dixon, William Graham, Stephen Miller, Robert Heckard, Dale Schelzel, Deborah S. White

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.

Original language	English (US)
Pages (from-to)	57-60
Number of pages	4
Journal	Cancer
Volume	51
Issue number	1
DOIs	https://doi.org/10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V
State	Published - Jan 1 1983

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

Cite this

@article{5d4ccfab54c548af902dea239fceb5b9,

title = "Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma",

abstract = "One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.",

author = "Allan Lipton and Harvey, {Harold A.} and Bellarmine Lawrence and Robert Gottlieb and Miodrag Kukrika and Richard Dixon and William Graham and Stephen Miller and Robert Heckard and Dale Schelzel and White, {Deborah S.}",

year = "1983",

month = jan,

day = "1",

doi = "10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V",

language = "English (US)",

volume = "51",

pages = "57--60",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

AU - Lipton, Allan

AU - Harvey, Harold A.

AU - Lawrence, Bellarmine

AU - Gottlieb, Robert

AU - Kukrika, Miodrag

AU - Dixon, Richard

AU - Graham, William

AU - Miller, Stephen

AU - Heckard, Robert

AU - Schelzel, Dale

AU - White, Deborah S.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.

AB - One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.

UR - http://www.scopus.com/inward/record.url?scp=0020659801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020659801&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

DO - 10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

M3 - Article

C2 - 6821809

AN - SCOPUS:0020659801

SN - 0008-543X

VL - 51

SP - 57

EP - 60

JO - Cancer

JF - Cancer

IS - 1

ER -

Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this